Eric A Nelson1, Nina V Kraguljac2, David M White2, Ripu D Jindal2,3, Ah L Shin2, Adrienne C Lahti2. 1. Department of Psychology, University of Alabama at Birmingham, AL, USA. 2. Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, AL, USA. 3. Birmingham Veteran Affairs Medical Center, AL, USA.
Abstract
BACKGROUND: Cortical thickness (CT) and gyrification are complementary indices that assess different aspects of gray matter structural integrity. Both neurodevelopment insults and acute tissue response to antipsychotic medication could underlie the known heterogeneity of treatment response and are well-suited for interrogation into the relationship between gray matter morphometry and clinical outcomes in schizophrenia (SZ). METHODS: Using a prospective design, we enrolled 34 unmedicated patients with SZ and 23 healthy controls. Patients were scanned at baseline and after a 6-week trial with risperidone. CT and local gyrification index (LGI) values were quantified from structural MRI scans using FreeSurfer 5.3. RESULTS: We found reduced CT and LGI in patients compared to controls. Vertex-wise analyses demonstrated that hypogyrification was most prominent in the inferior frontal cortex, temporal cortex, insula, pre/postcentral gyri, temporoparietal junction, and the supramarginal gyrus. Baseline CT was predictive of subsequent response to antipsychotic treatment, and increase in CT after 6 weeks was correlated with greater symptom reductions. CONCLUSIONS: In summary, we report evidence of reduced CT and LGI in unmedicated patients compared to controls, suggesting involvement of different aspects of gray matter morphometry in the pathophysiology of SZ. Importantly, we found that lower CT at baseline and greater increase of CT following 6 weeks of treatment with risperidone were associated with better clinical response. Our results suggest that cortical thinning may normalize as a result of a good response to antipsychotic medication, possibly by alleviating potential neurotoxic processes underlying gray matter deterioration.
BACKGROUND: Cortical thickness (CT) and gyrification are complementary indices that assess different aspects of gray matter structural integrity. Both neurodevelopment insults and acute tissue response to antipsychotic medication could underlie the known heterogeneity of treatment response and are well-suited for interrogation into the relationship between gray matter morphometry and clinical outcomes in schizophrenia (SZ). METHODS: Using a prospective design, we enrolled 34 unmedicated patients with SZ and 23 healthy controls. Patients were scanned at baseline and after a 6-week trial with risperidone. CT and local gyrification index (LGI) values were quantified from structural MRI scans using FreeSurfer 5.3. RESULTS: We found reduced CT and LGI in patients compared to controls. Vertex-wise analyses demonstrated that hypogyrification was most prominent in the inferior frontal cortex, temporal cortex, insula, pre/postcentral gyri, temporoparietal junction, and the supramarginal gyrus. Baseline CT was predictive of subsequent response to antipsychotic treatment, and increase in CT after 6 weeks was correlated with greater symptom reductions. CONCLUSIONS: In summary, we report evidence of reduced CT and LGI in unmedicated patients compared to controls, suggesting involvement of different aspects of gray matter morphometry in the pathophysiology of SZ. Importantly, we found that lower CT at baseline and greater increase of CT following 6 weeks of treatment with risperidone were associated with better clinical response. Our results suggest that cortical thinning may normalize as a result of a good response to antipsychotic medication, possibly by alleviating potential neurotoxic processes underlying gray matter deterioration.
Authors: Glenn T Konopaske; Karl-Anton Dorph-Petersen; Robert A Sweet; Joseph N Pierri; Wei Zhang; Allan R Sampson; David A Lewis Journal: Biol Psychiatry Date: 2007-10-22 Impact factor: 13.382
Authors: Li Kong; Christina J Herold; Frank Zöllner; David H Salat; Marc M Lässer; Lena A Schmid; Iven Fellhauer; Philipp A Thomann; Marco Essig; Lothar R Schad; Kirk I Erickson; Johannes Schröder Journal: Psychiatry Res Date: 2014-12-22 Impact factor: 3.222
Authors: Jeffrey A Lieberman; Gary D Tollefson; Cecil Charles; Robert Zipursky; Tonmoy Sharma; Rene S Kahn; Richard S E Keefe; Alan I Green; Raquel E Gur; Joseph McEvoy; Diana Perkins; Robert M Hamer; Hongbin Gu; Mauricio Tohen Journal: Arch Gen Psychiatry Date: 2005-04
Authors: Randy L Buckner; Denise Head; Jamie Parker; Anthony F Fotenos; Daniel Marcus; John C Morris; Abraham Z Snyder Journal: Neuroimage Date: 2004-10 Impact factor: 6.556
Authors: Joshua S Shimony; Christopher D Smyser; Graham Wideman; Dimitrios Alexopoulos; Jason Hill; John Harwell; Donna Dierker; David C Van Essen; Terrie E Inder; Jeffrey J Neil Journal: Neuroimage Date: 2015-11-06 Impact factor: 6.556
Authors: N Okada; M Fukunaga; F Yamashita; D Koshiyama; H Yamamori; K Ohi; Y Yasuda; M Fujimoto; Y Watanabe; N Yahata; K Nemoto; D P Hibar; T G M van Erp; H Fujino; M Isobe; S Isomura; T Natsubori; H Narita; N Hashimoto; J Miyata; S Koike; T Takahashi; H Yamasue; K Matsuo; T Onitsuka; T Iidaka; Y Kawasaki; R Yoshimura; Y Watanabe; M Suzuki; J A Turner; M Takeda; P M Thompson; N Ozaki; K Kasai; R Hashimoto Journal: Mol Psychiatry Date: 2016-01-19 Impact factor: 15.992